SCHEMBL10296730

SCHEMBL10296730

COc1cc(C)cc(CCCCCO)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 1/20 0.50
TNKS2 Q9H2K2 1/20 0.44
CNR1 P21554 4/20 0.42
CNR2 P34972 4/20 0.42
CALM1 P0DP23 3/20 0.40
AKR1B1 P15121 1/20 0.40
CYP4F2 P78329 2/20 0.39
CYP4A11 Q02928 2/20 0.39
ALOX15 P16050 2/20 0.39
IGF1R P08069 1/20 0.39
CYP19A1 P11511 1/20 0.39
HDAC1 Q13547 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
TACR1 P25103 1/20 0.38
LMNA P02545 1/20 0.38
PGR P06401 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
MAPT P10636 1/20 0.38
CYP2C9 P11712 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5275704 0.89 PTGS2 (0.56) PTGS2TNKS2CNR1CNR2CALM1
SCHEMBL1050377 0.89 PTGS2 (0.56) PTGS2TNKS2CNR1CNR2CALM1
SCHEMBL23266717 0.87 PTGS2 (0.58) PTGS2TNKS2CNR1CNR2CALM1
SCHEMBL11766486 0.85 CALM1 (0.44) PTGS2TNKS2CALM1AKR1B1CYP19A1
SCHEMBL8229999 0.84 PTGS2 (0.65) PTGS2CNR1CNR2CYP3A4
SCHEMBL29530874 0.81 CA2 (0.43) PTGS2TNKS2CNR1CNR2CYP4F2
SCHEMBL224550 0.81 TNKS2 (0.56) PTGS2TNKS2CNR1CNR2CALM1
SCHEMBL28266224 0.81 TNKS2 (0.41) PTGS2TNKS2CNR1CNR2CYP4F2
SCHEMBL15787170 0.81 PTGS2 (0.47) PTGS2CALM1AKR1B1CYP19A1TACR1
SCHEMBL13618169 0.79 PTGS2 (0.68) PTGS2CALM1AKR1B1CYP19A1TACR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120172339-A1 ANGIOGENIC RESORCINOL DERIVATIVES NORTHEASTERN UNIVERSITY (US) 2012-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120172339-A1 ANGIOGENIC RESORCINOL DERIVATIVES CNR1, CNR2, KDR PTGS2 587/4885TNKS2 3056/4885CNR1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.